Back to Search
Start Over
Engineering a novel biosynthetic pathway in Escherichia coli for the production of caffeine
- Source :
- RSC Advances. 7:56382-56389
- Publication Year :
- 2017
- Publisher :
- Royal Society of Chemistry (RSC), 2017.
-
Abstract
- Caffeine (Cf, 1,3,7-trimethylxanthine), a major secondary metabolite of many higher plants, is widely used in popular non-alcoholic beverages, and in the pharmaceutical and health industries. Currently, this valuable chemical is mainly manufactured by chemical synthesis. In this study, we developed a novel approach for de novo caffeine production in metabolically engineered Escherichia coli. Xanthine-to-caffeine conversion was first achieved by the expression of a plant-derived gene encoding tea caffeine synthase (TCS1). Caffeine accumulation was then increased using two metabolic strategies: higher-level expression of the target enzymes, and enhancement of xanthine and S-adenosyl-L-methionine biosynthesis. The final strain (BL21/pRSF-eCS1-SAM2-vgb-eGUD1) produced up to 21.46 ± 1.03 mg L−1 caffeine from 20 g L−1 of glucose in shake flask culture, yielding caffeine up to 2.96 mg g−1 glucose, which represents the highest titer of caffeine produced by fermentation reported to date. This novel microbial conversion also represents an innovative approach to produce value-added methylxanthine chemicals from cheap carbon sources.
- Subjects :
- 0301 basic medicine
chemistry.chemical_classification
Chemistry
General Chemical Engineering
General Chemistry
Secondary metabolite
Xanthine
medicine.disease_cause
Caffeine synthase
03 medical and health sciences
chemistry.chemical_compound
030104 developmental biology
Enzyme
Biosynthesis
Biochemistry
medicine
Fermentation
Caffeine
Escherichia coli
medicine.drug
Subjects
Details
- ISSN :
- 20462069
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- RSC Advances
- Accession number :
- edsair.doi...........1ad837591279f72112213aaea5ec2f66